Restless Legs Syndrome (RLS), also called Willis-Ekbom Disease, is a neurological disorder that causes an irresistible urge to move the legs. This urge is usually accompanied by unpleasant sensations like aching, itching, or crawling feelings that get worse during rest, especially at night. Movement often brings temporary relief, but the symptoms can severely disrupt sleep and daily life.
Recent research is shedding new light on the link between RLS and chronic kidney disease (CKD), opening doors to new treatments and management strategies.
A large body of evidence now shows that RLS is especially common in people with chronic kidney disease, particularly those who require dialysis. One meta-analysis published in 2016 estimated that nearly 25% of CKD patients suffer from RLS.
A major reason is iron deficiency, which is common in CKD patients because of chronic inflammation, restricted diets, and the blood loss that occurs during dialysis. Studies of brain imaging and spinal fluid samples have revealed that it’s not just low iron in the blood that matters—it’s iron deficiency in certain regions of the brain that interferes with dopamine production. Dopamine is a brain chemical essential for controlling movement, and problems in this system are strongly tied to RLS symptoms.
Researchers have also found that CKD patients with RLS tend to have lower serum ferritin and transferrin saturation—markers that confirm both absolute and functional iron deficiency.
Traditional Treatments – and Why They Are Changing
For many years, the first-line medical treatment for RLS was a class of drugs called dopamine agonists. Medications like pramipexole (Mirapex®) and ropinirole (Requip®) mimic dopamine and help control the uncomfortable sensations. They can work well in the short term, but over time, many patients develop a problem called augmentation, where symptoms start earlier in the day, grow more severe, and even spread to the arms and trunk.
Recognizing these issues, the American Academy of Sleep Medicine (AASM) published new guidelines in 2025 recommending that dopamine agonists should no longer be the first option. Dr. Brian Koo, a Yale Medicine neurologist who helped write the guidelines, emphasized that these drugs can worsen RLS in the long run, requiring higher doses and leading to serious side effects like confusion, compulsive behavior, and depression.
Instead, the AASM now strongly supports treatments that target iron deficiency. Iron infusions are often more effective than pills and have been shown to reduce RLS severity in many patients. Other recommended therapies include gabapentin and pregabalin, which calm nerve activity without causing augmentation. In severe cases, low-dose opioids may be considered under careful supervision.
Alongside medication changes, technology is creating new possibilities for managing RLS. One promising device is the TX100 Tonic Motor Activation (TOMAC) System, a wearable tool that stimulates nerves in the legs before bedtime. Clinical trials have shown it can significantly ease symptoms and improve sleep quality.
Researchers are also studying the benefits of meditative movement therapies like yoga and tai chi. A small clinical trial found that yoga can reduce RLS severity and improve sleep and mood without side effects. Other studies show that moderate aerobic exercise—like walking, swimming, or cycling—can help reduce symptoms for many people, although overly intense or late-night workouts sometimes worsen RLS.
Lifestyle Changes and Self-Care
While no cure exists, people with RLS can often reduce their symptoms through lifestyle adjustments. Doctors recommend avoiding caffeine, alcohol, and nicotine, particularly in the evening. Establishing a consistent sleep schedule and creating a calming bedtime routine can also help. Simple measures like warm baths, leg massages, or stretching before bed can offer relief.
Patients should also ask their doctors about testing for iron deficiency, as correcting it may make a big difference. For those with CKD, managing anemia and inflammation is particularly important.
The understanding of RLS is evolving quickly, especially in light of its connection to chronic kidney disease. The research underscores the importance of early diagnosis, iron-focused treatment, and personalized care. While dopamine agonists once seemed like miracle drugs, doctors now know they can lead to worsening symptoms over time.
Thanks to updated guidelines and innovative therapies, people living with RLS—and the doctors who care for them—have more options than ever before. For many, this means better sleep, improved mood, and the hope that new discoveries will one day bring lasting relief.
